-
An early diagnosis and some diet changes can decrease the risk of severe symptoms in children with BCKDK metabolic deficiency
The research, under the leadership of Dr. Àngels García-Cazorla at the Institut de Recerca Sant Joan de Déu, has demonstrated that early identification of this disease is possible through the standard neonatal screening test, also known as the heel prick test.
-
Artificial intelligence tool to predict neurodevelopmental progress of infants with low birth weight
Dr Carles Escera receives support from the Bosch i Gimpera Foundation to develop the project Artificial intelligence tool to predict neurodevelopmental progress of infants with low birth weight.
-
Experts in nanomedicine come together to tackle rare diseases
The fourth edition of the "Nanorare Disease Day" event was held on February 28th, in collaboration between the Institut de Recerca Sant Joan de Déu de Barcelona and NanomedSpain, on World Rare Disease Day.
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.
-
Dr. Joan Comella, new director of the Institut de Recerca Sant Joan de Déu
The Governing Council of the Institute de Recerca Sant Joan de Déu (IRSJD) has appointed Dr. Joan Comella as director of the Institute. We thank Dr. Francesc Palau for his years of dedication to the management.
-
Pro-inflammatory alterations identified in persons with non-specific low back pain
A study led by the Psychological Research on Fibromyalgia and Chronic Pain Group (AGORA Group) of the Institut de Recerca Sant Joan de Déu (IRSJD) · Parc Sanitari Sant Joan de Déu and the Universitat Autònoma de Barcelona (UAB) contributes new evidence on the immune-inflammatory state in non-specific low back pain.
-
A new European project is starting to create a European Youth Cancer Survivors Network
The EU-funded project "EU-CAYAS-NET" will develop a "European Youth Cancer Survivors Network" alongside an interactive virtual platform, with Institut de Recerca Sant Joan de Déu participation.
-
The most common type 2 diabetes drug needs the action of a cellular-stress-response protein to make effect
Metformin, the most prescribed drug for treating diabetes mellitus, known as type 2 diabetes, requires the presence of the growth differentiation factor 15 (GDF15) -a protein whose expression increases in response to cellular stress- to present its antidiabetic effects.
-
Dr Alexandra Avgustinova awarded a scientific excellence grant from the European Research Council (ERC)
The ERC Starting Grant will fund the project "Oncogenic competence during development - When, Where and Why?" led by Dr Alexandra Avgustinova (IRSJD), with approximately 1.5 million euros.
